In Vietnam, the first study in this field by Nguyen Van Bang et al (2014) on pregnant women with chronic HBV infection with HBV DNA load > 10 copies / ml, who received intervention with lamivudine (n = 33) and tenofovir (n = 49) at 32 nd week of pregnancy and 4 weeks postpartum. The results showed that both lamivudine and tenofovir proved effective in reducing HBV transmission from mother to child with the rate of HBV infection in children at 52 weeks of age was only 2.4%, of which the percentage in the group of mother treated with lamivudine was 3% and the group with the mother receiving tenofovir was 2%.